Lista de obras - Frances Alice Shepherd - Dominio Público Uruguay

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.

artículo científico publicado en 2017

A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium

artículo científico publicado en 2009

A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium

artículo científico

A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer

artículo científico publicado en 2012

A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.

artículo científico publicado en 2011

Adjuvant chemotherapy for resected early-stage non-small cell lung cancer

artículo científico publicado en 2015

Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study

artículo científico publicado en 2010

Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials

artículo científico publicado en 2008

Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.

artículo científico publicado en 2015

Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the NCIC Clinical Trials Group

artículo científico publicado en 2009

BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial

artículo científico publicado en 2016

Characterizing the cancer genome in lung adenocarcinoma

artículo científico publicado en 2007

Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline

artículo científico publicado en 2007

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer

artículo científico publicado en 2013

Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies

artículo científico publicado en 2012

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

artículo científico publicado en 2013

K-ras mutations in non-small-cell lung carcinoma: a review

artículo científico publicado en 2006

KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer

artículo científico publicado en 2007

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer

article

Lung cancer in 2013: state of the art therapy for metastatic disease

artículo científico publicado en 2013

Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors

artículo científico publicado en 2010

Lung cancer susceptibility locus at 5p15.33

artículo científico publicado en 2008

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

artículo científico publicado en 2013

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

artículo científico publicado en 2009

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

artículo científico publicado en 2016

NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer

artículo científico publicado en 2014

Novel candidate tumor marker genes for lung adenocarcinoma

artículo científico publicado en 2002

Optimized application of penalized regression methods to diverse genomic data

artículo científico publicado en 2011

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

artículo científico publicado en 2016

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

artículo científico publicado en 2008

Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer

artículo científico publicado en 2006

Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.

artículo científico publicado en 2010

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy

artículo científico publicado en 2017

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

artículo científico publicado en 2015

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy

artículo científico publicado en 2013

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer

artículo científico publicado en 2016

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis

artículo científico publicado en 2016

Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer

artículo científico publicado en 2010

Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer

artículo científico publicado en 2011

Prognostic gene signatures for non-small-cell lung cancer

artículo científico publicado en 2009

Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer

artículo científico publicado en 2011

Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.

artículo científico publicado en 2011

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer

artículo científico publicado en 2014

Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

artículo científico publicado en 2009

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

artículo científico publicado en 2009

Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer

artículo científico publicado en 2014

Resident preparedness in discussing prognosis in patients with advanced lung cancer.

artículo científico publicado en 2009

Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada

artículo científico publicado en 2014

Small cell lung cancer and targeted therapies.

artículo científico publicado en 2007

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

artículo científico publicado en 2013

TRIM14 is a Putative Tumor Suppressor and Regulator of Innate Immune Response in Non-Small Cell Lung Cancer

artículo científico publicado en 2017

The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency.

artículo científico publicado en 2017

The IASLC Lung Cancer Staging Project: data elements for the prospective project

artículo científico publicado en 2009

Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.

scientific article published on December 2008

Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America

artículo científico publicado en 2002

Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.

artículo científico publicado en 2006

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

artículo científico publicado en 2005

Lista de obras de Frances Alice Shepherd

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.

A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium

A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium

A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer

A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.

Adjuvant chemotherapy for resected early-stage non-small cell lung cancer

Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study

Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials

Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.

Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the NCIC Clinical Trials Group

BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial

Characterizing the cancer genome in lung adenocarcinoma

Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer

Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

K-ras mutations in non-small-cell lung carcinoma: a review

KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer

Lung cancer in 2013: state of the art therapy for metastatic disease

Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors

Lung cancer susceptibility locus at 5p15.33

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer

Novel candidate tumor marker genes for lung adenocarcinoma

Optimized application of penalized regression methods to diverse genomic data

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer

Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis

Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer

Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer

Prognostic gene signatures for non-small-cell lung cancer

Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer

Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer

Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer

Resident preparedness in discussing prognosis in patients with advanced lung cancer.

Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada

Small cell lung cancer and targeted therapies.

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

TRIM14 is a Putative Tumor Suppressor and Regulator of Innate Immune Response in Non-Small Cell Lung Cancer

The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency.

The IASLC Lung Cancer Staging Project: data elements for the prospective project

Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.

Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America

Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer